The uridine diphosphoglucuronosyltransferases (UGTs) belong to a superfamily of enzymes that catalyse the glucuronidation of numerous endobiotics and xenobiotics. Several human hepatic and extrahepatic UGT isozymes have been characterized with respect to their substrate specificity, tissue expression and gene structure. Genetic polymorphisms have been identified for almost all the UGT family members. A wide variety of anticancer drugs, dietary chemopreventives and carcinogens are known to be conjugated by members of both UGT1A and UGT2B subfamilies. This review examines in detail each UGT isozyme known to be associated with cancer and carcinogenesis. The cancer-related substrates for several UGTs are summarized, and the functionally relevant genetic polymorphisms of UGTs are reviewed. A number of genotype-phenotype association studies have been carried out to characterize the role of UGT pharmacogenetics in several types of cancer, and these examples are discussed here. In summary, this review focuses on the role of the human UGT genetic polymorphisms in carcinogenesis, chemoprevention and cancer risk.
Introduction
Glucuronidation is a major conjugation pathway in the metabolism and excretion of endobiotics and xenobiotics. This reaction is catalysed by the superfamily of enzymes named uridine diphosphoglucuronosyltransferases (UGTs). Although glucuronidation is commonly thought of as a detoxification mechanism, there are several examples of active and/or toxic glucuronide metabolites in the literature (Burchell and Coughtrie, 1989) . The UGTs catalyse the transfer of the glucuronic acid moiety from the co-substrate UDP-glucuronic acid to the substrate, resulting in a metabolite with greater polarity and water solubility. Several UGT isozymes exist, and 18 human liver cDNAs have been cloned to date (Burchell, 2003) . Genetic polymorphisms are known to exist in human UGT genes, and various studies have examined the role of this genetic variation in the glucuronidation of carcinogens as well as anticancer drugs. The effect of UGT polymorphisms on the prevalence rates of various types of cancer has also been studied. The substrate specificity, tissue-specific expression and relevance in different disease states of the UGT isozymes have been reviewed elsewhere (Burchell and Coughtrie, 1989; Miners and Mackenzie, 1991; Tukey and Strassburg, 2000; Burchell, 2003; Wells et al., 2004) . With new polymorphisms being frequently discovered in UGT genes, this chapter aims at providing an updated and comprehensive review of genetic variation in the UGT gene family, and its relevance to cancer.
The UGT superfamily
The UGTs are membrane-bound proteins found in the subcellular microsomal endoplasmic reticulum fraction. The catalytic domain of these enzymes faces the lumen of the endoplasmic reticulum, and microsomal preparations require activation with detergents or pore-forming agents before biochemical activity determination (Burchell and Coughtrie, 1989; Fisher et al., 2000) . Putative functions have been assigned to various domains of the UGT protein based on amino-acid sequences of the cDNA and purified protein (Burchell and Coughtrie, 1989; Kalies and Hartmann, 1998; Meech and Mackenzie, 1998; Ouzzine et al., 1999) . Figure 1 depicts a hypothetical structure with putative functional domains of the UGTs. The nomenclature of individual UGT family members is based on gene sequence homology; thus, the superfamily is divided into two subfamilies, UGT1A and UGT2B (Mackenzie et al., 1997) .
Gene structures of the UGT1A and 2B subfamilies The UGT1 gene has been localized to human chromosome 2 at 2q37, and consists of four common exons and at least 13 variable exons (Clarke et al., 1997; Gong et al., 2001) . The organization of the UGT1A locus is represented in Figure 2 . This locus contains 13 cassette exons at the 5 0 -end, and four 3 0 -end exons that are common for every UGT1A RNA (Owens and Ritter, 1995) . The 5 0 -lanking region of each first-exon cassette contains promoter elements for the initiation of transcription. Transcription combines an individual first exon with common exons 2-5 to yield unique UGT1A transcripts. The UGT1 subfamily of enzymes catalyses the glucuronidation of bilirubin and xenobiotic amines and phenols. A large number of xenobiotics is conjugated by the UGT1A isozymes, and some pharmacologically relevant substrates include analgesics, sex hormones, anticancer drugs like irinotecan and flavopiridol, and tobacco-specific carcinogens including polycyclic aromatic hydrocarbons and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (Kiang et al., 2005) .
In contrast to the UGT1A shared-exon locus, the UGT2B subfamily consists of individual genes as part of a gene cluster localized on human chromosome 4 at 4q13-q21 (Riedy et al., 2000) . The UGT2B family members include UGT2B4, 2B7, 2B10, 2B11, 2B15, 2B17 and 2B28, along with some recently discovered pseudogenes (Riedy et al., 2000) . These subfamily members catalyse the glucuronidation of bile acids, steroids and several therapeutic drugs (Kiang et al., 2005) .
Many UGT isozymes catalyse the glucuronidation of anticancer agents as well as carcinogens, contributing significantly to the overall disposition and pharmacological effect of these xenobiotics. Genetic polymorphisms have been discovered in almost all the UGTs, and as discussed below, the role of UGT pharmacogenetics is very important in the pharmacokinetics and pharmacodynamics of carcinogens and chemopreventives. It should be noted here that in the ensuing text we have typically referred to these genetic variants as polymorphisms. However, for those variants whose allele frequency has not been determined, or has been determined to be below 1%, consistent with convention, these genetic changes are denoted as 'mutations'.
Individual UGT isozymes and substrate specificity A wide variety of drugs and other xenobiotics are known to be glucuronidated in the human body, and UGT isozymes show broad overlapping substrate specificity toward these chemicals (Miners and Mackenzie, 1991; Tukey and Strassburg, 2000) . Thus, while an endogenous substrate like bilirubin is almost exclusively glucuronidated via UGT1A1, acetaminophen is a phenolic substrate of several UGT1A and 2B isozymes (Court et al., 2001) . Other simple phenols such as p-nitrophenol, a-naphthol and 4-methylumbelliferone are commonly used to determine total UGT activity in tissue samples. Serotonin has been reported to be a highly specific substrate for UGT1A6 (King et al., 1999; Krishnaswamy et al., 2003) , while UGT2B7 catalyses the glucuronidation of both zidovudine and morphine (Coffman et al., 1997; Barbier et al., 2000) . The UGT proteins are differentially expressed both in the liver and in various extrahepatic tissues (Tukey and Strassburg, 2000) . The highly conserved structure of the UGTs, along with differential tissue expression and overlapping substrate specificity, indicate a critical role of these proteins in the detoxification and elimination of lipophilic xenobiotics and endobiotics from the body.
UGTs catalyse the glucuronidation of a large number of environmental carcinogens, dietary chemopreventives and chemotherapeutics. Some important examples of chemicals involved in cancer incidence and prevention, along with the UGT isozymes responsible for their conjugation, are presented in Table 1 . There are additional examples of investigational anticancer agents that are also glucuronidated. Drugs such as topotecan, doxorubicin and 4-hydroxytamoxifen are known to be glucuronidated; however, the specific UGT isozymes involved in these reactions are as yet unknown (McCague et al., 1990; Platzer et al., 1998; Rosing et al., 1998; Andersen et al., 1999) . Estrogens, progestins and androgens are also glucuronidated, and may be an important means of circulation of the inactive form of the hormone in the body, although sulfation appears to be a predominant depot mechanism for estrogens. Several studies have determined associations between UGT genotypes, steroid hormone glucuronidation, and UGT pharmacogenetics S Nagar and RP Remmel Adapted from Tukey and Strassburg (2000) and Desai et al. (2003) . risk and incidence of cancer (Lampe et al., 2000; MacLeod et al., 2000; Park et al., 2004; Sparks et al., 2004; Nowell et al., 2005) . Another important example is that of all-trans-retinoic acid (ATRA) and its glucuronide (Barua and Sidell, 2004) . This retinoyl beta-glucuronide is an active metabolite without the toxic side effects of the parent ATRA, and has been suggested as a safe and effective alternative to ATRA and other retinoids currently utilized in clinical trials for neuroblastoma and other cancers. ATRA is a substrate for human UGT2B7 (Table 1) (Gestl et al., 2002) . The individual UGT polymorphisms and their correlation with cancer incidence will be discussed in detail below. In general, while correlations between cancer risk and therapy for these polymorphic variants may be obscured by virtue of the fact that these enzymes metabolize both carcinogens as well as chemopreventive and chemotherapeutic agents, some significant correlations have been observed (see below).
UGT1A1
The physiological role of UGT1A1 has been appreciated for several years now, with the finding that it is the primary isozyme responsible for the glucuronidation and detoxification of bilirubin (Bosma et al., 1994) . Unconjugated hyperbilirubinemias such as Gilbert's syndrome (mild, asymptomatic) and Crigler-Najjar syndromes (severe, symptomatic) have been studied extensively, and this work has led to the identification and characterization of over 60 UGT1A1 mutations. Recently, the role of UGT1A1 polymorphisms in the disposition of the anticancer drug irinotecan has received much attention.
UGT1A1 variants and genotype frequencies
To date, more than 60 UGT1A1 variants associated with unconjugated hyperbilirubinemia have been reported, and 33 of these are reviewed in Tukey and Strassburg (2000) . Of these variants, the UGT1A1*28 variant with a promoter polymorphism responsible for most of the Gilbert's syndrome subjects in Caucasians (10-20%) has been extensively studied. Among the other mutations, some are intronic while a majority of mutations is located within the exons 1-5. In Asian populations, several exon 1 mutations such as UGT1A1*6 (G71R), *7 (Y486D) and *27 (P229Q) contribute significantly to mild to moderate hyperbilirubinemia. The two most recently reported mutations are a 715C-T nucleotide change in exon 1, leading to a truncated protein (Nong et al., 2005) , and a 686C-T nucleotide change in exon 1 that causes a P229L protein change (Kaniwa et al., 2005) . Table 2 summarizes some UGT1A1 mutations reported to date that have been characterized in pharmacogenetic studies.
The UGT1A1*28 mutation is characterized by a TA insertion in the regulatory TATA box of the UGT1A1 promoter; thus, while the wild-type UGT1A1*1 has six TA repeats, the low activity *28 variant has seven TA inserts (Bosma et al., 1995; Monaghan et al., 1996) . An inverse correlation between the number of TA repeats and bilirubin-glucuronidating activity of UGT1A1 has been reported (Beutler et al., 1998) . Thus, variants with five TA repeats have the highest activity, followed by six TA repeats with intermediate activity, and seven or eight TA repeats with low activity.
The genotype frequency of the UGT1A1*28 promoter polymorphism has been evaluated in different populations. In a Scottish population, 40% of healthy subjects were reported to have the 6/6 genotype, 48% had the heterozygous 6/7 genotype and 12% had the 7/7 genotype (Monaghan et al., 1996) . A study with an African-American population reported a high 7/7 frequency of 23% in these subjects, with a smaller percentage of eight TA repeats (Beutler et al., 1998) . The 7/7 genotype also seems to be common in the Indian population, with a reported frequency of 13% (Balram et al., 2002) . In contrast, both Japanese and Chinese populations seem to have low 7/7 genotype frequencies (Ando et al., 1998; Balram et al., 2002) . A recent study determined UGT1A1*28 genotype frequencies in an Egyptian population; here, the frequencies in 100 Caucasian subjects for 6/6, 6/7 and 7/7 genotypes were 50, 42 and 8%, compared with 56, 36 and 8% in 50 Egyptian subjects (Kohle et al., 2003) . Several other studies have evaluated UGT1A1*28 genotype population frequencies and have reported similar results (Monaghan et al., 1997; Biondi et al., 1999; Lampe et al., 1999; Borlak et al., 2000; Te Morsche et al., 2001 ).
UGT1A1 polymorphisms and cancer: genotype-phenotype correlation
The UGT1A1 promoter polymorphism has been extensively studied in the context of irinotecan disposition. Irinotecan (CPT-11) is a camptothecin drug used in the treatment of colorectal cancer (CRC). Irinotecan is hydrolysed by carboxyesterases and converted to its active phenolic metabolite SN-38, a topoisomerase I inhibitor. SN-38 is further glucuronidated to its inactive glucuronide (SN-38G) in hepatic as well as extrahepatic tissues by UGT1A1, 1A7, 1A8, 1A9 and 1A10 (Gagne et al., 2002) . Iyer et al. (1999) conducted an in vitro study with human liver microsomes from 44 subjects; the study determined that bilirubin and SN-38 glucuronidation rates decreased with increasing TA repeats in the UGT1A1 promoter TATA box. A retrospective study with 118 Japanese cancer patients in irinotecan therapy identified 26 patients with severe toxicity (Ando et al., 2000) . Of these 26 patients, four (15%) patients were homozygous for UGT1A1*28 versus three (3%) of 92 patients exhibiting no toxicity. The heterozygous UGT1A1*1/*28 genotype was found in eight (31%) patients with severe toxicity and in 10 (11%) patients without toxicity. Multivariate analysis of these data showed that the UGT1A1*28 allele was a significant risk factor for irinotecan-related severe toxicity. Additionally, three patients were heterozygous for the UGT1A1*27 mutation, and all three suffered from severe toxicity. A multigenic study involving an in-travenous infusion of CPT-11 to 65 cancer patients concluded that the UGT1A1*28 genotype correlated with a slight but statistically insignificant decrease in SN-38 glucuronidation (Mathijssen et al., 2003) . However, a UGT1A1 haplotype study in Japanese patients reported a significant association between the *28 genotype and both increased total bilirubin and decreased SN-38G/SN-38 area under the concentration-time curve (AUC) ratio upon a 90-min infusion of CPT-11 (Sai et al., 2004) . Additionally, this reduction in AUC ratio was significant in samples with the UGT1A1*6 (211 G>A; G71R) þ *28 haplotype, as compared with the *1/*1 group. Another study conducted in 94 Caucasian gastrointestinal (GI) cancer patients concluded that the UGT1A1*28 allele correlated with a reduced SN38G/SN-38 ratio, whereas UGT1A9 polymorphisms were not associated with AUC reduction (Paoluzzi et al., 2004) . However, as discussed below in detail, several UGT1A7 and UGT1A9 variant alleles have also been shown to be associated with decreased SN-38 glucuronidation in addition to UGT1A1 variants (Villeneuve et al., 2003) . Other UGT1A1 variants besides *28, namely the *6 allele (G71R), *7 (Y486D) and *27 (P229Q), have been examined for their SN-38-glucuronidating capacity, and the Y486D variant has been shown to have drastically UGT pharmacogenetics S Nagar and RP Remmel reduced activity toward SN-38 in vitro (Jinno et al., 2003c) . Thus, it remains to be conclusively determined whether UGT1A1*28 genotyping alone is a sufficient indicator of irinotecan pharmacokinetic variability. In Asian populations, other common exon 1 variants should be considered besides UGT1A1*28. An important factor in irinotecan pharmacology is its toxicity, manifested as life-threatening neutropenia and diarrhea. Innocenti et al. (2004) examined UGT1A1 variants -3279 G>T, À3156 G>A, *28, *6 and *27 for their correlation with severe neutropenia upon irinotecan treatment. The authors reported that six of 63 patients had grade 4 neutropenia; of these, the prevalence of toxicity was three of six patients with the 7/7 genotype, three of 24 with the 6/7 genotype and zero of 29 with the 6/6 genotype. It was concluded that the UGT1A1*28 genotype correlates with severe neutropenia upon irinotecan treatment. Rouits et al. (2004) obtained results similar to Innocenti et al. with respect to neutropenia in 75 advanced CRC patients receiving CPT-11 þ 5-fluorouracil. Five of seven homozygous 7/7 patients had severe neutropenia, compared with 14 of 35 6/7 patients and only three of 31 6/6 patients. There was a significant difference among the three groups. In contrast to the study by Innocenti et al., this study had a higher incidence of diarrhea. Interestingly, diarrhea did not correlate with UGT1A1 genotype in this study population, perhaps owing to reduced enterohepatic recycling of SN-38G and a lower intestinal exposure to SN-38. However, Marcuello et al. (2004) contradicted these findings in that the UGT1A1*28 genotype associated with diarrhea but not neutropenia in 95 patients with metastatic CRC. Additionally, as with irinotecan pharmacokinetics, UGT1A7 and 1A9 have been reported to predict irinotecan toxicity (Carlini et al., 2005) . Many studies cited here varied in their study design, and all studies examined different patient populations. In single centers, the small number of patients available for study, and different dosing and comedications may explain the differing results. It is clear that although the UGT1A1*28 polymorphism plays an important role in irinotecan disposition and toxicity, other UGT1A1 variants as well as other UGTs need to be studied extensively in this context. The UGT1A1*6 variant (211 G>A; G71R) is prevalent in Chinese and Japanese populations, and has been studied in conjunction with UGT1A7 polymorphisms (discussed below) in the context of risk for developing CRC . This case-control study consisted of a Taiwanese population, and enrolled 268 CRC cases and 441 controls. Logistical regression of the data indicated that the odds ratio (OR) for developing CRC with the UGT1A1*6 allele was 2.03 (Po0.001), and this ratio increased to 2.34 with a UGT1A1*6 plus a UGT1A7 variant. Among the patients, the OR of developing metastases with the UGT1A1*6 variant was 4.89 (Po0.001). Thus, risk and outcome of CRC may well be correlated with polymorphic variation in the UGTs.
UGT1A1 polymorphisms have also been studied for other carcinomas. Several studies have focused on UGTs and breast cancer risk and incidence. Several breast cancer cell lines have been shown to express UGT1A1 (Guillemette et al., 2000a) . A case-control study with 200 African-American subjects per group was conducted, with the hypothesis that breast cancer cases would have higher prevalence of the UGT1A1*28 allele, owing to its lower glucuronidating activity toward estradiol (Guillemette et al., 2000a) . A 1.8-fold elevation in risk for invasive breast cancer in premenopausal women with a low-activity UGT1A1 genotype was reported; this association was stronger in estrogen receptor-negative (ERÀ) breast cancer compared to ER þ cancer. However, in a subsequent larger study that analysed 455 Caucasian breast cancer cases and 609 controls, no association between UGT1A1 genotype and breast cancer risk or hormone levels was established . Sparks et al. (2004) recently reported a reduced risk for ERÀ breast cancer associated with the UGT1A1*28 genotype. The study enrolled 163 female breast cancer patients, monitored sex hormone levels and genotyped subjects for UGT1A1, 2B4, 2B7, 2B15 and sulfotransferase 1A1. A majority of the enrolled women was postmenopausal, and hormone levels were monitored and reported only for postmenopausal patients. The prevalence of UGT1A1*28 alleles was reported to correlate with a reduced risk for ERÀ breast cancer (P for trend ¼ 0.03). Additionally, estradiol, estrone and testosterone levels were monitored, and mean estradiol levels varied with UGT1A1 genotype. In a large Chinese study with 1047 breast cancer cases and 1083 controls, subjects were genotyped for the UGT1A1 promoter TATA polymorphism (Adegoke et al., 2004) . The study found an elevated risk for breast cancer in women under the age of 40 years with the UGT1A1*28 allele, but found no association between UGT1A1 genotype and ER status. Unfortunately, the other common low activity UGT1A1 polymorphisms present in Chinese were not determined. Taken together, these studies again point out the complexity of a multigenic disease like breast cancer. Detoxification of catechol estrogens by other UGT enzymes in breast tissue may also play a critical role in estrogen-related carcinogenesis. Genotyping for UGT1A1 is indeed a useful pharmacogenetic tool, but there is definitely a need for haplotype and multigene analysis before disease risk and outcome can be predicted using pharmacogenetics.
Among other work examining the association between UGT1A1 genotype and cancer, a recent exploratory study examined the role of enzyme and transporter polymorphisms in irinotecan disposition in 29 nasopharyngeal carcinoma patients (Zhou et al., 2005) . Of the 11 candidate genes studied, polymorphisms in the drug transporter genes were found to affect irinotecan disposition. Endometrial cancer risk and its association with the UGT1A1*28 variant was characterized in 222 cases and 666 matched controls (Duguay et al., 2004b) . The low-activity UGT1A1*28 allele was found to associate with decreased risk of endometrial cancer, presumably by decreasing the glucuronidation and excretion of the antiproliferative 2-hydroxy estradiol in the endometrium. Finally, human liver microsomes were genotyped for the UGT1A1 TATA box polymorphism, and the *28 variant was shown to have significantly decreased activity toward the promutagen benzo(a)pyrene-trans-7R,8R-dihydrodiol (Fang and Lazarus, 2004) .
UGT1A3
UGT1A3 cDNA has been isolated and sequenced, and expressed in human COS-7 cells for functional assays (Mojarrabi et al., 1996) . The enzyme expression is low in the liver but high in the intestine. The 55 kDa protein expressed in COS cells exhibited activity toward estrone, 2-hydroxyestrone, and 6-and 12-hydroxy benzo[a]pyrene. Human UGT1A3 expressed in HEK293 or Chinese hamster lung cells was shown to have activity toward catechol estrogens, several amine substrates, anthraquinones and chemopreventive flavonoids such as naringenin and quercetin (Cheng et al., 1998b; Green et al., 1998; Chen et al., 2005) . Recently, the isozyme was found to catalyse the glucuronidation of an investigational anticancer agent, TA-1801A (Kaji and Kume, 2005) . Thus, several UGT1A3 substrates play a role in carcinogenesis, chemoprevention and cancer therapy. Table 2 summarizes some functionally relevant UGT1A3 polymorphisms. The allele frequencies reported in two independent studies are similar, despite the different populations characterized in each study (Ehmer et al., 2004; Iwai et al., 2004) . Iwai et al. (2004) reported six single-nucleotide polymorphisms (SNPs) in exon 1 of UGT1A3. Several mutants were expressed in COS-7 cells, and it was determined that contrary to several UGT mutants with diminished activity, the UGT1A3 variants W11R and W11R þ V47A exhibited much greater activity toward estrone than the wild type. The same SNPs were concurrently reported by another group, where the authors additionally characterized the prevalence of these polymorphisms in 470 healthy controls and 258 hepatocellular carcinoma (HCC) patients (Ehmer et al., 2004) . No significant difference was found in the allele frequencies between controls and cancer patients.
UGT1A3 polymorphisms and their role in cancer
No other studies examining UGT1A3 genotypephenotype correlations have been reported to our knowledge. As UGT1A3 catalyses the conjugation of a variety of substrates including catechol estrogens, benzopyrenes and flavonoids, it is plausible that polymorphisms in this gene will play an important role in inter-individual variability in cancer risk, incidence and management.
UGT1A4
A total of 19 SNPs and two frameshift mutations have been reported in the UGT1A4 gene, and polymorphisms with known functional effects are summarized in Table 2 . Of these 21 mutations, eight lead to aminoacid changes, five are silent mutations, whereas the remaining eight are in non-coding regions of the gene (Ehmer et al., 2004; Saeki et al., 2005a) . Haplotype analysis of the detected SNPs resulted in the assignment of 16 observed haplotypes in a Japanese population (Saeki et al., 2005a) .
The frequency of two SNPs, codon 24 C>A and codon 48 T>G, was determined in a German Caucasoid population including 470 healthy controls and 258 HCC patients (Ehmer et al., 2004) . There was no significant difference in the frequencies between controls and patients. When expressed in HEK293 cells, both variants exhibited decreased activity toward benzidine, androsterone and dihydrotestosterone compared to the wild-type protein. For the mutations reported by Saeki et al (2005a) , again no significant differences were found between allele frequencies of 60 healthy volunteers and 88 cancer patients.
As with UGT1A3, numerous UGT1A4 substrates play a role in cancer (Table 1) . These substrates include the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), the bladder cancer -causing agent benzidine, compounds present in tobacco including nicotine, cotinine and NNAL, and the anticancer drug tamoxifen (Malfatti and Felton, 2001; Zenser et al., 2002; Kuehl and Murphy, 2003; Kaku et al., 2004; Wiener et al., 2004a) . A recent study examined UGT1A4 genotype-phenotype correlations between UGT1A4 polymorphisms and NNAL N-glucuronidation (Wiener et al., 2004b) . In vitro incubations with 78 human liver microsome samples indicated that livers homozygous for the T24P variant were associated with higher production of NNAL N-glucuronide. The glucuronidation of NNAL is an important detoxification pathway for NNAL and its precursor 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Hence, the UGT1A4 T24P variant genotype may, in fact, be protective against tobacco carcinogens. Additionally, if this variant proves to have altered activity toward other UGT1A4 substrates like tamoxifen and PhIP, polymorphisms in UGT1A4 may prove to be important in predicting outcome in several types of cancers. Lazarus et al. (2005) have also recently examined a mutation in UGT2B17 and NNAL glucuronidation.
UGT1A6
UGT1A6 is expressed in several tissues in the human body, and catalyses the glucuronidation of small planar phenols and primary aromatic amines. Early studies detected two functionally important SNPs in exon 1 of the UGT1A6 gene (Table 2) , and the resultant variant had altered activity toward several substrates (Ciotti et al., 1997) . The discovery of a third SNP at codon 7 led to four haplotypes being defined, and the variant UGT1A6 protein was shown to have altered activity both in human liver microsomes and when expressed in HEK293 cells (Nagar et al., 2004) . The allele frequencies in this report were similar in Caucasians and African Americans. Comparable allele frequencies have also been reported in Caucasian and Egyptian subjects (Kohle et al., 2003) . Recently, novel polymorphisms have additionally been reported in the 5 0 -regulatory region, exon 1 and intron 1 (Table 2) (Krishnaswamy et al., 2005a; Saeki et al., 2005b) . A linkage between the UGT1A1*28 and UGT1A6 541 A>G/552 A>C variants has been reported in various studies (Lampe et al., 1999; Kohle et al., 2003; Peters et al., 2003) .
UGT1A6 and CRC
UGT1A6 catalyses the glucuronidation of aspirin and acetaminophen. The role of UGT1A6 genetic polymorphisms was examined in the context of aspirin use and colon adenoma risk in 474 adenomatous polyp cases and 563 controls (Bigler et al., 2001 ). An inverse relationship was observed between colon adenoma risk among aspirin users and the variant UGT1A6 (541 A>G/552 A>C) allele. Chan et al. (2005) prospectively examined this association in 1062 Caucasian women. Although UGT1A6 genotype was not associated with overall adenoma risk, the variant genotype did modify the effect of aspirin on adenoma. Among 616 women with the variant UGT1A6 genotype, regular aspirin use was associated with decreased adenoma risk (multivariate OR for adenoma ¼ 0.66; 95% CI 0.45-0.95). Such an association was not found among women with the wild-type genotype . Thus, it has been hypothesized that the 'low-activity' UGT1A6 variant leads to increased salicylate levels in aspirin users, leading to decreased prostaglandin levels and a lower risk of colon neoplasia. The 19 T>G polymorphism was not taken into account in these studies; it is important to note that the variants in the study by Nagar et al. had a higher activity toward p-nitrophenol and a-naphthol compared to the wild-type UGT1A6 protein, in both human liver microsomes and expressed in HEK293 cells. Work by Ciotti et al. had also shown that the activity of the variant UGT1A6 proteins differed according to substrate. Recent studies by Krishnaswamy et al. (2005b) corroborate these results, in that the variant UGT1A6 allozymes expressed in HEK293 cells exhibited higher activity than wild-type protein toward several substrates, including the specific substrate serotonin. However, in the same study, this difference was not significant in human liver microsomes obtained from genotyped donors. Thus, UGT1A6 variants need to be classified as 'low' or 'high' activity carefully, taking into account the specific substrate that is being examined.
UGT1A6 polymorphisms have also been examined in the context of irinotecan efficacy and toxicity in colorectal carcinoma, but no significant genotype-phenotype association was observed (Carlini et al., 2005) . Finally, UGT1A6 phenotypes were compared in matched tumor (primary HCC or metastases of primary colorectal tumors) and normal tissues (Nagar et al., 2004) . There was no tumor-associated loss of heterozygosity, and no differences in activity or immunoreactive protein were found between primary versus metastatic tumors.
UGT1A7
Polymorphisms first reported in UGT1A7 resulted in amino-acid changes N129K, R131K and W208R, and were shown to have decreased activity compared to the wild-type protein (Guillemette et al., 2000b) . Other SNPs and resulting haplotypes have since been discovered in this gene (Table 2 ). UGT1A7*3 has been found to be in linkage with UGT1A1*28 in Caucasian as well as Egyptian populations (Kohle et al., 2003) . The effect of UGT1A7 polymorphisms has been characterized in several studies focusing on different cancers. A summary of the results is provided below.
Proximal GI tract cancer UGT1A7 catalyses the conjugation and detoxification of several tobacco-related carcinogens. It is primarily expressed in the esophagus, orolaryngeal tissue and gastric epithelium, and its role in proximal GI tract cancer has been studied (Strassburg et al., 1999; Zheng et al., 2001) . In a UGT1A7 pharmacogenetic study, 194 orolaryngeal cancer cases and 388 controls were genotyped for the high-activity wild-type UGT1A7*1 and its intermediate-to low-activity variants *2, *3 and *4 (amino-acid changes N129K, R131K and W208R; Table 2 ) (Zheng et al., 2001 ). An increased orolaryngeal cancer risk was reported for all subjects with the lowactivity UGT1A7 genotype; the OR for this risk was higher in African Americans (OR 6.2; 95% CI 1.2-31) compared to Caucasians (OR 3.7; 95% CI 1.7-8.7). The risk of oral cavity as well as laryngeal cancer was similar among the low-activity UGT1A7 groups. Interestingly, this risk was not significant in non-smokers, whereas the low-activity UGT1A7 genotype did increase cancer risk in light and heavy smokers. UGT1A7 has high catalytic activity toward PAH phenols, and thus may serve as a detoxifying enzyme in these target tissues. In another study by Vogel et al. (2002) , 76 proximal GI tract cancer patients and 210 controls were genotyped for UGT1A7, and the *3 allele was reported to be associated with greater cancer risk in 32% of the patients.
Hepatocellular carcinoma
UGT polymorphisms have been characterized in the context of HCC. The variant UGT1A7 *3 allele was first reported to be associated with HCC in a group of 59 patients; low-activity UGT1A7 polymorphisms were reported in 93.2% of these patients (Vogel et al., 2001 ). Subsequently, a Japanese population of 280 hepatitis C virus (HCV)-infected patients was genotyped for UGT1A7 among other related genes to characterize pharmacogenetics of HCV-associated HCC (Wang et al., 2004) . Again, low-activity UGT1A7 variants were found to be associated with incidence of HCC in this population. A larger study including 217 HCC patients and 291 controls corroborated these findings when it was reported that the low-activity UGT1A7 polymorphisms correlated with HCC risk (OR 3.06; 95% CI 1.50-6.24) (Tseng et al., 2005) . Additionally, in male patients, the age of onset was earlier in the low-activity UGT1A7 genotypes, as against males with the wild-type allele (median age 50 versus 59 years, Po0.05). As UGT1A7 is not expressed in the liver, a plausible mechanistic explanation is not clear, but may involve a haplotype linkage to other UGT enzymes.
Colorectal cancer
Several studies have examined the association between UGT1A7 polymorphisms and CRC. Strassburg et al. (2002) reported a low presence of the wild-type UGT1A7*1 allele in 78 Caucasian CRC patients (9 versus 20% among 210 controls). The authors also reported a high number of patients (50%) having at least one copy of the *3 allele, as compared to controls (27%). A significant association between the UGT1A7*3 allele and CRC incidence was reported (OR 2.75; 95% CI 1.6-4.71). In another study with 371 Caucasian colorectal carcinoma patients and 415 controls, no significant differences in the UGT1A7*3 allele frequency were reported between cases and controls (van der Logt et al., 2004) . However, age-and genderadjusted associations were reported between UGT1A7 variant genotypes and alleles, and CRC. Recently, UGT1A1*6 (G71R) and UGT1A7*3 polymorphisms were examined together for their association with colorectal carcinoma . Again, the UGT1A7*1/*3 genotype and the *3 allele were found to have significant association with CRC. Interestingly, the presence of both the UGT1A1*6 variant and the UGT1A7*3 variant increased the odds of CRC incidence. Butler et al. examined the risk of CRC with UGT1A7 genotype and exposure to dietary heterocyclic amines (HCAs). The report found no association between UGT1A7 low-versus high-activity genotype and CRC incidence. However, UGT1A7 variants had an additive effect with HCA exposure; thus, the risk for colon cancer was significantly associated with low UGT1A7 activity plus increased HCA exposure (Butler et al., 2005) .
In the context of CRC, irinotecan disposition and its association with UGT1A7 genetic polymorphisms has been evaluated. UGT1A7 variants were shown to have decreased activity toward irinotecan in stable expression systems in mammalian cells (Gagne et al., 2002; Villeneuve et al., 2003) . A trial with Japanese CRC patients found no differences in UGT1A7 allele frequencies between cases and controls (Ando et al., 2002) . Additionally, no association was found between UGT1A7 variants and irinotecan-related toxicity. However, Carlini et al. (2005) reported a significant association between low-activity UGT1A7 genotypes and irinotecan-related antitumor response as well as lack of severe diarrhea. In comparison to the study by Ando et al., the UGT1A7*2 and *3 allele frequencies were markedly greater in this study population; additionally, drug administration regimens were different in the two studies. It remains to be evaluated if UGT1A7 polymorphisms indeed have an effect on irinotecan disposition and pharmacology in CRC, as UGT1A7 expression in the colon is negligible in humans.
Pancreatic cancer and lung cancer
Two studies have examined the role of UGT1A7 polymorphisms in pancreatic cancer. Significant UGT1A7 expression was observed in human pancreatic tissue (Ockenga et al., 2003) . In a group of 52 Caucasian pancreatic adenocarcinoma patients, cancer incidence was associated with the UGT1A7*3 allele, and this association was stronger in smokers younger than 55 years (Ockenga et al., 2003) . In a larger study by Verlaan et al. (2005) , UGT1A7*1, *2, *3, *10 and *11 alleles were identified. The study included 973 patients with acute and chronic pancreatitis as well as pancreatic adenocarcinoma, and 1532 healthy and alcoholic controls. UGT1A7 genotype frequencies were found to be similar in all control and case groups, and no association between UGT1A7 polymorphisms and pancreatic disease was found. Finally, a recent report suggested a correlation between the UGT1A7*3 allele and *3/*3 genotype, and incidence of lung cancer in a Japanese population of 113 patients and 178 controls (Araki et al., 2005) . The *3/*3 genotype frequency was significantly greater in cases compared to controls in this study.
UGT1A8
The high sequence homology of UGT1A7, 1A8, 1A9 and 1A10 (>90%) and their extrahepatic expression have been reported (Strassburg et al., 1998) . Human UGT1A8 has catalytic activity toward estrogens and dietary flavonoids (Table 1; Cheng et al., 1998a; Lepine et al., 2004) . Functionally significant genetic polymorphisms have been reported for this UGT family member. Two non-synonymous SNPs have been reported in the UGT1A8 gene (Table 2 ). In the report by Huang et al. (2002) , the *1 and *2 variants were found to have comparable activity toward a variety of substrates, while *3 was reported to be inactive.
Only a few studies have examined the role of UGT1A8 polymorphisms in disease states. Human UGT1A8 has been shown to catalyse the glucuronidation of SN-38, the active metabolite of irinotecan, albeit with a low catalytic efficiency (Gagne et al., 2002) . The polymorphic variants of UGT1A8 were not studied for this substrate. UGT1A8 pharmacogenetics were considered in chronic pancreatitis, but no association was found between UGT1A8 variants and disease in the Caucasian case-control population characterized (Verlaan et al., 2004) . The only other pharmacogenetic study of UGT1A8 examined its role in risk and incidence of CRC. Again, no association was determined between UGT1A8 polymorphisms and CRC in this study, despite high expression in the intestinal tract (van der Logt et al., 2004) . Thus, the possible role of UGT1A8 in cancer remains to be evaluated. This isozyme may be important in cancer, considering that many of its substrates play an important role in carcinogenesis as well as chemoprevention. UGT1A8 has high activity toward many flavonols and flavonoids, and limits the bioavailability of these potential chemopreventive agents.
UGT1A9
As many as 20 mutations have been identified in the UGT1A9 gene, including its upstream and intronic regions, defining more than 15 haplotypes; of these, several mutations have been examined for functional variability as well as their potential role in irinotecan disposition ( Table 2) . Frequencies of different mutations associated with this gene have been reported to vary in ethnic populations (Villeneuve et al., 2003; Innocenti et al., 2005) . Gagne et al. (2002) reported significant catalytic activity of UGT1A9 toward SN-38 glucuronidation. An exon 1 766 G>A substitution identified in a Japanese population resulted in a D256N amino-acid change; this variant was found to have a catalytic efficiency toward SN-38 less than 5% that of the wild type, when expressed transiently in COS cells (Jinno et al., 2003a) . Two other polymorphisms UGT1A9*2 (8 G>A; C3Y) and *3 (98 T>C; M33 T) were identified and evaluated via stable expression in HEK293 cells (Villeneuve et al., 2003) . The genotype frequencies reported were significantly different between Caucasians and African Americans; the *1/*2 genotype was absent in Caucasians and present in 5% of the African Americans genotyped. The *1/*3 genotype, on the other hand, was present in about 4% of the Caucasian subjects, but absent in the African Americans (Villeneuve et al., 2003) . These studies also resulted in the interesting observation that while UGT1A9*2 exhibited similar activity as the wild type *1 toward both SN-38 and flavopiridol, the *3 variant had decreased activity toward SN-38 but not flavopiridol. A commonly found single base thymidine insertion in a promoter region of UGT1A9 results in A(T) 10 AT compared with the reference A(T) 9 AT (Yamanaka et al., 2004) . Luciferase reporter assays indicated that the A(T) 10 AT construct had almost threefold higher activity than the A(T) 9 AT construct. Protein levels as well as activity toward substrates have been shown to vary with several UGT1A9 promoter polymorphisms (Girard et al., 2004) .
The influence of two UGT1A9 mutations, M33T and D256N, on irinotecan disposition was examined in Caucasian patients with malignant solid tumors (Paoluzzi et al., 2004) . These mutations were found to be rare in this study population (one of 94 patients), and no association between UGT1A9 variants and irinotecan pharmacokinetics was noted. In another study examining the role of UGT polymorphisms in irinotecan response and toxicity, 66 colorectal carcinoma patients were genotyped for UGT1A9 (Carlini et al., 2005) . A total of six mutations were reported for UGT1A9, of which two were promoter polymorphisms and four were in intronic regions. The authors noted a statistically significant trend between the A(T) 9 AT homozygous genotype and efficacious tumor response. This genotype also associated significantly with a lower incidence of irinotecan-related severe diarrhea. A comprehensive study of UGT1A9 pharmacogenetics needs to be carried out in order to evaluate the role of these complicated genetic polymorphisms in anticancer drug disposition.
UGT1A10
UGT1A10 is expressed in several extrahepatic tissues and catalyses the glucuronidation of several cancerrelated substrates (Table 1) . It has low catalytic activity toward SN-38 (Gagne et al., 2002) . Nine SNPs have been reported in the UGT1A10 gene to date ( Table 2 ). The two UGT1A10 variants T202I and M59I were characterized by transient expression in COS-1 cells (Jinno et al., 2003b) . The variant T202I exhibited decreased activity in this system, whereas the M59I change did not result in significant activity change. The only other study focusing on UGT1A10 polymorphisms has examined its role in orolaryngeal carcinoma risk (Elahi et al., 2003) . Elahi et al. reported six UGT1A10 polymorphisms (including three non-synonymous SNPs) in three racial groups. The frequency of both the E139K and L244I amino-acid changes was significantly higher in African Americans compared with Caucasians, and these mutations were absent in Asians. The role of these polymorphisms in orolaryngeal cancer risk was evaluated in 115 African Americans and 115 matched controls (Elahi et al., 2003) . Individuals with the 139E allele were found to have a significantly lower risk for orolaryngeal carcinoma, whereas no association was found between cancer and the L244I variant. The functional activity of these variants remains to be determined.
UGT2B4
Several cancer-related compounds such as androsterone, 4-hydroxyestrone, hydroxycotinine and bile acids are glucuronidated by UGT2B4 (Table 1 ). The structure of the UGT2B4 gene has been characterized (Monaghan et al., 1997) . Several mutations have been reported for UGT2B4, with the D458E amino-acid change being the most commonly evaluated (Table 3) . While genetic polymorphisms and genotype frequencies have been established for UGT2B4, only a few studies have examined the role of these polymorphisms in disease risk and incidence (Levesque et al., 1999; Lampe et al., 2000) . To date, a single study has examined UGT2B4 genetic variation in the context of cancer. As sex hormone levels are affected by genetic polymorphisms in the UGTs, 163 breast cancer patients were genotyped for UGT2B4 among other genes, and associations between genotype and ERÀ or progesterone receptornegative tumors were examined (Sparks et al., 2004) . No associations or trends were observed between cancer status and UGT2B4 genotype.
UGT2B7
UGT2B7 catalyses the glucuronidation of a wide variety of substrates including NSAIDs and morphine. Of the numerous mutations reported for this gene, three are non-synonymous SNPs that result in amino-acid changes (Table 3) . Promoter-reporter gene assays have indicated decreased activity of promoter variants in vitro, but these results need to be validated in human subjects (Duguay et al., 2004a) . The first UGT2B7 variant to be reported was the C>T transversion at nucleotide 802, resulting in an H268Y amino-acid change, and with an overall prevalence of 50% in Caucasians (Bhasker et al., 2000) . The variant did not cause a change in activity toward the substrates androsterone and morphine in human liver microsomes in this study. Morphine pharmacokinetics were also unaffected by this variant in cancer patients on chronic morphine therapy (Holthe et al., 2002) . The subsequent identification of additional UGT2B7 polymorphisms did not help explain interindividual differences in morphine pharmacokinetics (Holthe et al., 2003) . Interestingly, a case report of two cancer patients with markedly different responses to morphine indicated that the patients differed in their UGT2B7 genotype at 12 different positions on the gene, in addition to having different m-opioid receptor genotypes (Hirota et al., 2003) . Thus, it may be useful to identify all the relevant mutations and haplotypes for UGT2B7, before useful genotype-phenotype associations can be evaluated.
The effects of UGT2B7 polymorphisms may additionally be substrate specific. In a study evaluating the glucuronidation of the tobacco carcinogen NNAL, 78 human liver microsomes stratified by UGT genotype were evaluated for activity toward NNAL (Wiener et al., 2004b) . Microsomes from subjects with the UGT2B7 268Y homozygous genotype exhibited significantly lower activity toward NNAL than those from 268H homozygous subjects. Additionally, a significantly higher number of livers with low NNAL-O-glucuronide formation had the homozygous 268Y genotype. Finally, the UGT2B7 H268Y variant was studied for its role in ERÀ or progesterone receptor-negative tumors, but no genotype-phenotype associations were noted (Sparks et al., 2004) .
UGT2B15
A multitude of intronic and non-coding region polymorphisms have recently been reported for UGT2B15, an enzyme with significant activity toward androgens (Iida et al., 2002) . However, only three non-synonymous SNPs have been reported in the coding region (Table 3) . Lampe et al. (2000) reported varying allele and genotype frequencies for UGT2B15 D85Y in Asian versus Caucasian populations. UGT2B15 is known to be highly expressed in prostate cancer cell lines (Levesque et al., 1998; Belanger et al., 2003) . A matched casecontrol study including 155 Caucasian prostate cancer patients and 115 controls found a significant association between the UGT2B15 85D homozygous genotype and cancer incidence (OR ¼ 2.7; 95% CI 1.1-6.6) (Park et al., 2004) . While UGT2B15 catalyses the conjugation of several cancer-related substrates including tamoxifen, no other study has examined the role of UGT2B15 polymorphisms in cancer. The only other pharmacogenetic study to date has examined UGT2B15 polymorphisms and oxazepam glucuronidation, and the lowactivity D85Y variant has been indicated as a possible factor explaining variable S-oxazepam conjugation .
Summary
The UGT superfamily of enzymes catalyses the conjugation of a wide variety of substrates, many of which play important and varied roles in carcinogenesis. Several members of the UGT family of enzymes are now known to be polymorphic, and functional studies have revealed significant differences in activity of genetically variant polymorphs. Several phenotypes associate with polymorphisms in the UGT genes, and this genetic variation has correlated with risk and incidence of different cancers. Thus, UGT polymorphisms appear to play an important role in orolaryngeal, GI, colorectal, lung, breast, pancreatic and prostate cancers. Although much research has already been directed toward studying the role of these polymorphisms in cancer, several UGT family members remain to be completely characterized. Additionally, with the large number of mutations now known, it will be important to consider linkage among mutations as well as haplotypes of various genes involved in a pathway before more meaningful correlations can be arrived at. It is also critical to conduct functional studies to determine the role, if any, of several known mutations, as not all the known mutations in the UGTs will translate to in vivo phenotypic changes. Further work will clarify the role of UGT genetic variation in cancer risk, incidence and prevention. 
